研究团队对7例TNBC患者(HER2-negative vs HER2-low,4 vs 3)的36168个细胞进行单细胞RNA测序(scRNA-seq),以进一步探索两种不同表型的TNBC之间肿瘤生物学特性的差异。结果显示: 与HER2-low TNBC相比,HER2-negativeative TNBC内皮细胞(1.8%对8...
[18]Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 t...
a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Research. 2023;83(5_Supplement):GS3-02.
[24]Cantini L, Trapani D, Guidi L, Boscolo Bielo L, et al. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer. Cancer Treat Rev. 2024 Feb;123:102669. [25]Curigliano G, Castelo-Branco L...
Sara M Tolaney et al. Lancet Oncol. 2023 Mar;24(3):273-285.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial 编辑|r.G 审核|贾巍教授...
对于HER2 低表达的 TNBC 患者,NP-S 联合曲妥珠单抗及 GM-CSF 作为术后辅助治疗,3 年无病生存率显著提高(94.1% vs 66.9%,P = 0.01)。 HER2 低表达乳腺癌的治疗面临的挑战 HER2 低表达重塑乳腺癌的分子分型 近期,《Lancet Oncology》发表了一篇文章,文章对乳腺癌术前新辅助治疗 4 项前瞻临床试验中随机入组...
Tolaney SM, Barry WT, Guo H, et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol. 2017;35(15_suppl):511. Pivot X, Romieu G, Debled M, et al. PHARE randomized trial fi...
基于DESTINY-Breast04研究结果,德曲妥珠单抗(T-DXd)获得美国食品药品监督管理局(FDA)和我国国家药品管理管理局(NMPA)批准用于HER2低表达(IHC+或IHC2+/ISH-)乳腺癌患者。这是乳腺癌治疗史上首次正式批准对于HER2低表达人群的治疗,宣告传统抗HER2治疗“非阴即阳”的
如今,随着DESTINY-Breast04研究展现出了对HER2低表达(HER2-low)乳腺癌实施抗HER2治疗的更好效果,临床对HER2-low人群的关注度也日益提升[1]。由于乳腺癌转移灶与原发灶之间、进展前后存在时空异质性,其HER2状态也可能随之改变。因此,韩国学者开展了一项回顾性研究,分析了乳腺癌疾病进展过程中HER2-low状态的改变状况,...
近日在npj Breast Cancer期刊上发表了题为“Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer”的研究,比较了TNBC和HR阴性HER2阳性的肿瘤患者的肿瘤免疫微环境,以探索其潜在的相似或不同之处。肿瘤免疫微环境: HER2 阳性乳腺癌患者...